Icotrokinra – First Oral IL‑23R Antagonist for Psoriasis.
FDA approved icotrokinra for moderate to severe plaque psoriasis in adults and adolescents (≥12 years, ≥40 kg) who are candidates for systemic therapy or phototherapy.
First and only oral targeted IL‑23 receptor antagonist, offering a once daily pill.
A once daily oral option for patients stepping up from topical therapy or seeking an alternative to injectables.
It has favorable safety profile, supporting potential use in first line systemic therapy
Long‑term data show that about 8–9 out of 10 patients who achieved PASI 90 maintained clear skin after 52 weeks, including adolescents.
What real world data will be most important to confirm long‑term safety and durability?
MBH/PS
